Cargando…

Quality assessment and Q-markers discovery of Tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit

BACKGROUND: The limited therapeutic outcomes of atherosclerosis (AS) have allowed, traditional Chinese medicine has been well established as an alternative approach in ameliorating AS and associated clinical syndromes. Clinically, Tongsaimai tablet (TSMT), a commercial Chinese patent medicine approv...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yanfen, Xiao, Meng, Chen, Jiamei, Wang, Di, Hu, Yichen, Zhang, Chenfeng, Wang, Tuanjie, Fu, Chaomei, Wu, Yihan, Zhang, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438231/
https://www.ncbi.nlm.nih.gov/pubmed/36056398
http://dx.doi.org/10.1186/s13020-022-00658-9
_version_ 1784781782921510912
author Cheng, Yanfen
Xiao, Meng
Chen, Jiamei
Wang, Di
Hu, Yichen
Zhang, Chenfeng
Wang, Tuanjie
Fu, Chaomei
Wu, Yihan
Zhang, Jinming
author_facet Cheng, Yanfen
Xiao, Meng
Chen, Jiamei
Wang, Di
Hu, Yichen
Zhang, Chenfeng
Wang, Tuanjie
Fu, Chaomei
Wu, Yihan
Zhang, Jinming
author_sort Cheng, Yanfen
collection PubMed
description BACKGROUND: The limited therapeutic outcomes of atherosclerosis (AS) have allowed, traditional Chinese medicine has been well established as an alternative approach in ameliorating AS and associated clinical syndromes. Clinically, Tongsaimai tablet (TSMT), a commercial Chinese patent medicine approved by CFDA, shows an obvious therapeutic effect on AS treatment. However, its effective mechanism and quality control still need thorough and urgent exploration. METHODS: The mice were orally administered with TSMT and their serum was investigated for the absorbed compounds using serum pharmacochemistry via the UPLC-Q-Exactive Orbitrap/MS analysis was employed to investigate these absorbed compounds in serum of mice orally administrated with TSMT. Based on these absorbed prototype compounds in serum derived from TSMT, a component-target-disease network was constructed using network pharmacology strategy, which elucidated the potential bioactive components, effective targets, and molecular mechanisms of TSMT against AS. Further, the screened compounds from the component-target network were utilized as the quality control (QC) markers, determining multi-component content determination and HPLC fingerprint to assess quality of nine batches of TSMT samples. RESULTS: A total of 164 individual components were identified in TSMT. Among them, 29 prototype compounds were found in serum of mice administrated with TSMT. Based on these candidate prototype components, 34 protein targets and 151 pathways related to AS were predicted, and they might significantly exhibit potential anti-AS mechanisms via synergistic regulations of lipid regulation, shear stress, and anti-inflammation, etc. Five potentially bioactive ingredients in TSMT, including Ferulic acid, Liquiritin, Senkyunolide I, Luteolin and Glycyrrhizic acid in quantity not less than 1.2798, 0.4716, 0.5419, 0.1349, 4.0386 mg/g, respectively, screened from the component-target-pathway network. Thereby, these indicated that these five compounds of TMST which played vital roles in the attenuation of AS could serve as crucial marker compounds for quality control. CONCLUSIONS: Overall, based on the combination of serum pharmacochemistry and network pharmacology, the present study firstly provided a useful strategy to establish a quality assessment approach for TSMT by screening out the potential anti-AS mechanisms and chemical quality markers. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-022-00658-9.
format Online
Article
Text
id pubmed-9438231
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94382312022-09-03 Quality assessment and Q-markers discovery of Tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit Cheng, Yanfen Xiao, Meng Chen, Jiamei Wang, Di Hu, Yichen Zhang, Chenfeng Wang, Tuanjie Fu, Chaomei Wu, Yihan Zhang, Jinming Chin Med Research BACKGROUND: The limited therapeutic outcomes of atherosclerosis (AS) have allowed, traditional Chinese medicine has been well established as an alternative approach in ameliorating AS and associated clinical syndromes. Clinically, Tongsaimai tablet (TSMT), a commercial Chinese patent medicine approved by CFDA, shows an obvious therapeutic effect on AS treatment. However, its effective mechanism and quality control still need thorough and urgent exploration. METHODS: The mice were orally administered with TSMT and their serum was investigated for the absorbed compounds using serum pharmacochemistry via the UPLC-Q-Exactive Orbitrap/MS analysis was employed to investigate these absorbed compounds in serum of mice orally administrated with TSMT. Based on these absorbed prototype compounds in serum derived from TSMT, a component-target-disease network was constructed using network pharmacology strategy, which elucidated the potential bioactive components, effective targets, and molecular mechanisms of TSMT against AS. Further, the screened compounds from the component-target network were utilized as the quality control (QC) markers, determining multi-component content determination and HPLC fingerprint to assess quality of nine batches of TSMT samples. RESULTS: A total of 164 individual components were identified in TSMT. Among them, 29 prototype compounds were found in serum of mice administrated with TSMT. Based on these candidate prototype components, 34 protein targets and 151 pathways related to AS were predicted, and they might significantly exhibit potential anti-AS mechanisms via synergistic regulations of lipid regulation, shear stress, and anti-inflammation, etc. Five potentially bioactive ingredients in TSMT, including Ferulic acid, Liquiritin, Senkyunolide I, Luteolin and Glycyrrhizic acid in quantity not less than 1.2798, 0.4716, 0.5419, 0.1349, 4.0386 mg/g, respectively, screened from the component-target-pathway network. Thereby, these indicated that these five compounds of TMST which played vital roles in the attenuation of AS could serve as crucial marker compounds for quality control. CONCLUSIONS: Overall, based on the combination of serum pharmacochemistry and network pharmacology, the present study firstly provided a useful strategy to establish a quality assessment approach for TSMT by screening out the potential anti-AS mechanisms and chemical quality markers. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-022-00658-9. BioMed Central 2022-09-02 /pmc/articles/PMC9438231/ /pubmed/36056398 http://dx.doi.org/10.1186/s13020-022-00658-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cheng, Yanfen
Xiao, Meng
Chen, Jiamei
Wang, Di
Hu, Yichen
Zhang, Chenfeng
Wang, Tuanjie
Fu, Chaomei
Wu, Yihan
Zhang, Jinming
Quality assessment and Q-markers discovery of Tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit
title Quality assessment and Q-markers discovery of Tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit
title_full Quality assessment and Q-markers discovery of Tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit
title_fullStr Quality assessment and Q-markers discovery of Tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit
title_full_unstemmed Quality assessment and Q-markers discovery of Tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit
title_short Quality assessment and Q-markers discovery of Tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit
title_sort quality assessment and q-markers discovery of tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438231/
https://www.ncbi.nlm.nih.gov/pubmed/36056398
http://dx.doi.org/10.1186/s13020-022-00658-9
work_keys_str_mv AT chengyanfen qualityassessmentandqmarkersdiscoveryoftongsaimaitabletbyintegratingserumpharmacochemistryandnetworkpharmacologyforantiatherosclerosisbenefit
AT xiaomeng qualityassessmentandqmarkersdiscoveryoftongsaimaitabletbyintegratingserumpharmacochemistryandnetworkpharmacologyforantiatherosclerosisbenefit
AT chenjiamei qualityassessmentandqmarkersdiscoveryoftongsaimaitabletbyintegratingserumpharmacochemistryandnetworkpharmacologyforantiatherosclerosisbenefit
AT wangdi qualityassessmentandqmarkersdiscoveryoftongsaimaitabletbyintegratingserumpharmacochemistryandnetworkpharmacologyforantiatherosclerosisbenefit
AT huyichen qualityassessmentandqmarkersdiscoveryoftongsaimaitabletbyintegratingserumpharmacochemistryandnetworkpharmacologyforantiatherosclerosisbenefit
AT zhangchenfeng qualityassessmentandqmarkersdiscoveryoftongsaimaitabletbyintegratingserumpharmacochemistryandnetworkpharmacologyforantiatherosclerosisbenefit
AT wangtuanjie qualityassessmentandqmarkersdiscoveryoftongsaimaitabletbyintegratingserumpharmacochemistryandnetworkpharmacologyforantiatherosclerosisbenefit
AT fuchaomei qualityassessmentandqmarkersdiscoveryoftongsaimaitabletbyintegratingserumpharmacochemistryandnetworkpharmacologyforantiatherosclerosisbenefit
AT wuyihan qualityassessmentandqmarkersdiscoveryoftongsaimaitabletbyintegratingserumpharmacochemistryandnetworkpharmacologyforantiatherosclerosisbenefit
AT zhangjinming qualityassessmentandqmarkersdiscoveryoftongsaimaitabletbyintegratingserumpharmacochemistryandnetworkpharmacologyforantiatherosclerosisbenefit